# Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer

> **NCT07662252** · — · NOT_YET_RECRUITING · sponsor: **Federico II University** · enrollment: 186 (estimated)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer (TNBC)
- HER2 + Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07662252
- **Lead sponsor:** Federico II University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-10
- **Final completion:** 2029-06
- **Target enrollment:** 186 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662252, "Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*